Cargando…
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
BACKGROUND: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety. METH...
Autores principales: | Ascierto, Paolo Antonio, Del Vecchio, Michele, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, McNeil, Catriona, Rutkowski, Piotr, Loquai, Carmen, Mortier, Laurent, Hamid, Omid, Bastholt, Lars, Dreno, Brigitte, Schadendorf, Dirk, Garbe, Claus, Nyakas, Marta, Grob, Jean-Jacques, Thomas, Luc, Liszkay, Gabriella, Smylie, Michael, Hoeller, Christoph, Ferraresi, Virginia, Grange, Florent, Gutzmer, Ralf, Pikiel, Joanna, Hosein, Fareeda, Simsek, Burcin, Maio, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279645/ https://www.ncbi.nlm.nih.gov/pubmed/32503946 http://dx.doi.org/10.1136/jitc-2019-000391 |
Ejemplares similares
-
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
por: Ascierto, Paolo A, et al.
Publicado: (2014) -
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014) -
Comparison of the anesthetic effects between 5 mg/kg of alfaxalone and 10 mg/kg of propofol administered intravenously in cats
por: TAMURA, Jun, et al.
Publicado: (2021) -
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
por: Altomonte, Maresa, et al.
Publicado: (2013) -
Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto(®) Chew (25 mg/kg fluralaner) or Simparica TRIO(®) (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
por: Reif, Kathryn E., et al.
Publicado: (2023)